Taipei-based biotech company Jyong Biotech Ltd. has leveraged a successful IPO to accelerate the development of MCS-2, a promising treatment for benign prostatic hyperplasia (BPH).
The Left Line Shield Machine of the Jiao-Feng Section on the North Extension of Guangzhou Metro Line 8 Project Successfully Launched, Project Enters "Dual-Line Tunneling" Mode